Citations

Clear

4207 citation(s) found for "Chen, Yu".

The Rise of Medicare Advantage is Impacting the Fidelity of Traditional Medicare Claims Data
Chen, Xiao T. , Habermann, Elizabeth B. , Heckmann, Nathanael D. , Callaghan, John J. , Lewallen, David G. , Berry, Daniel J. , Bedard, Nicholas A. , Glasgow, Amy E , Heckmann, Nathanael , Callaghan, John J , Lewallen, David G , Berry, Daniel J , Habermann, Elizabeth , Bedard, Nicholas A

Mayo Clinic

Journal of Bone and Joint Surgery | April 25, 2025 | Volume: 107 | Issue: 12 | Pages: 1371-1376

10.2106/jbjs.24.00993 | PMID 40279407 Get It

Background: Traditional Medicare (TM) claims data are widely used by researchers and registries to report survivorship following total knee arthroplasty (TKA). The purpose of the present study was to investigate whether the mass exodus of patients from TM to Medicare Advantage (MA) has compromised the fidelity of TM data. Methods: We identified 11,717 Medicare-eligible patients (15,282 knees) who had undergone primary TKA from 2000 to 2020 at a single institution. Insurance type was analyzed, and 84% of TKAs were covered by TM. The rates of survivorship free from revision or reoperation were calculated for patients with TM coverage. The same survivorship end points were recalculated after censoring of patients who transitioned to MA after primary TKA, thereby modeling the impact of losing patients from the TM dataset. Differences in survivorship were compared. The mean duration of follow-up was 10 years. Results: From 2000 to 2020, there was a decrease in TM insurance (from 94% to 68%) and a corresponding increase in MA insurance (from 0% to 19%) among patients undergoing TKA. Following TKA, 25% of patients with TM coverage switched to MA. For patients with TM at the time of surgery, the 15-year rates of survivorship free from any reoperation or revision were 90% and 96%, respectively. When patients were censored upon transition from TM to MA, the 15-year rates of survivorship free from any reoperation (92% versus 90%; hazard ratio [HR] = 1.2; p = 0.001) or any revision (97% versus 96%; HR = 1.3; p = 0.002) were significantly higher. Conclusions: One in 4 patients left TM for MA after primary TKA, effectively making them lost to follow-up within TM datasets. The mass exodus of patients out of TM resulted in falsely elevated estimates of survivorship free from reoperation and from revision, with increasing divergence in survivorship over time, when MA data were excluded. As MA continues to grow, efforts to incorporate these data will become increasingly important. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
Abstract LB416: SAVANNAH: Clearance of plasma EGFRm in patients with EGFRm MET-overexpressed (OverExp) and/or -amplified (Amp) NSCLC post-osimertinib (osi) treated with savolitinib (savo) + osi
Riess, Jonathan W. , Marinis, Filippo de , Levy, Benjamin , Bonanno, Laura, Chu, Quincy S. , Novello, Silvia, Baik, Christina S. , Bazhenova, Lyudmila, Cadranel, Jacques , Yang, Tsung‐Ying , Chang, Gee‐Chen , Leventakos, Konstantinos , Livi, Lorenzo, Sequist, Lecia V. , Argue, John R., Xu, Wanning , Ahn, Myung‐Ju , Kim, Tae Min , Bonanno, Laura, Tiseo, Marcello , Sacher, Adrian Gerold , Novello, Silvia , Bazhenova, Lyudmila , Metro, Giulio , Yang, Cheng‐Ta , Livi, Lorenzo, Yang, James Chih‐Hsin , Argue, John, Markovets, Aleksandra A. , Hartmaier, Ryan James

Mayo Clinic

Cancer Research | April 25, 2025 | Volume: 85 | Issue: 8_Supplement_2 | Pages: LB416-LB416

10.1158/1538-7445.am2025-lb416 Get It

Abstract Background: Savo is an oral, potent and highly selective MET-TKI. In the Phase 2 SAVANNAH study (NCT03778229), savo + osi had a high rate of durable responses in pts with EGFRm advanced NSCLC and high MET OverExp and/or Amp levels. Early clearance of plasma EGFRm may predict outcomes. We report an exploratory analysis of plasma EGFRm clearance and its association with MET tissue biomarker status, ORR and PFS. Methods: Pts with EGFRm advanced NSCLC and MET OverExp and/or Amp with PD on 1L+ osi received savo 300 mg QD, 300 mg BID or 600 mg QD + osi 80 mg QD. MET OverExp/Amp was centrally confirmed (by IHC [Roche], 3+ intensity in ≥50% of tumor cells [MET IHC3+/≥50%]; by FISH [Abbott Molecular], MET gene copy number ≥5 or MET:CEP7 ratio ≥2 [FISH5+], or at higher thresholds of MET IHC3+/≥90% or FISH10+). Baseline (BL) and Wk 3 plasma EGFRm (Ex19del/L858R) were analyzed by ddPCR (Biodesix) as an estimate of tumor burden. MET Amp was not monitored in ctDNA due to low detection sensitivity. Clearance was defined as undetected EGFRm ctDNA at Wk 3, when detected at BL. PFS was investigator-assessed (RECIST 1.1). DCO: Aug 23, 2024. Results: Of 344 pts with evaluable BL ctDNA, 259 (75%) had detected EGFRm ctDNA. Of these, 225 had evaluable ctDNA at Wk 3 (82 [36%] had EGFRm clearance at Wk 3). Confirmed ORR was higher in pts with EGFRm Wk 3 clearance (56/82; 68%) vs non-clearance (38/143; 27%). PFS was longer in pts with vs without EGFRm clearance at Wk 3 (Table). Across all pts evaluable for ctDNA at Wk 3, clearance rates were higher in pts with vs without high MET (69/162 [43%] vs 13/63 [21%]; odds ratio [95% CI] 0.35 [0.16, 0.72]). Similar results were seen in the savo 300 mg QD + osi subgroup. Conclusions: In SAVANNAH, among pts with detected EGFRm ctDNA at BL, clearance at Wk 3 was associated with improved ORR and PFS. Plasma EGFRm clearance at Wk 3 is enriched in pts with MET IHC3+/≥90% or FISH10+ status, consistent with improved efficacy in this biomarker subgroup. Citation Format: Jonathan W. Riess, Filippo de Marinis, Benjamin Levy, Tae Min Kim, Laura Bonanno, Quincy Chu, Marcello Tiseo, Adrian Sacher, Silvia Novello, Christina Baik, Lyudmila Bazhenova, Jacques Cadranel, Giulio Metro, Cheng-Ta Yang, Tsung-Ying Yang, Gee-Chen Chang, Konstantinos Leventakos, Lorenzo Livi, James Chih-Hsin Yang, Lecia V. Sequist, John Argue, Wanning Xu, Aleksandra Markovets, Ryan Hartmaier, Myung-Ju Ahn. SAVANNAH: Clearance of plasma EGFRm in patients with EGFRm MET-overexpressed (OverExp) and/or -amplified (Amp) NSCLC post-osimertinib (osi) treated with savolitinib (savo) + osi [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr LB416.
Abstract CT112: Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of FXX489 ([177Lu]Lu-NNS309) in patients with pancreatic, lung, breast and colorectal cancers
Geva, Ravit , Juneau, Daniel , Ferrario, Cristiano , Moradi, Farshad , Iravani, Amir , Ahnert, Jordi, Rúiz, I., Koessler, Thibaud, Ferrandiz, Aitana Calvo, Spéville, Bernard Doger de , Razak, Albiruni R. Abdul, Al-Mansour, Laure, Nienhuis, Hilde H. , Eiber, Matthias , Heuschkel, Martin, Geoffrey, J Lane, Origuchi, Shizuka, Couillebault, Xuan Mai, Garayoa, Elisa Garcı́a, Roopa, Jayarama Naidu, Straub, Christopher, Hainzl, Dominik, Chen, Xinyu , Yang, Fang , Pectasides, Eirini, Mancini, B.R. , Esfahani, Shadi A. , Ahnert, Jordi, Ruiz, Ivan Manuel Victoria, Ferrandiz, Aitana Calvo, Flamen, Patrick , Deandreis, Désirèe , Schaefer, Niklaus , Nagarajah, James , Maccauro, Marco , Filice, Angelina , Goldman, Jonathan W. , Hermann, Ken , Drzezga, Alexander E. , McConathy, Jonathan , Geoffrey, Johnson, Parent, Ephraim E. , Kuboki, Yasutoshi , Couillebault, Xuân-Mai

Mayo Clinic

Cancer Research | April 25, 2025 | Volume: 85 | Issue: 8_Supplement_2 | Pages: CT112-CT112

10.1158/1538-7445.am2025-ct112 Get It

Abstract Background: Fibroblast activation protein (FAP) is a type II integral membrane glycoprotein, highly expressed on the cell surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial cancers and showing limited expression in normal tissues. Given this expression profile, FAP appears to be a promising target for radioligand therapy that has pan-cancer potential. [177Lu]Lu-NNS309 is a FAP-targeted radiopharmaceutical that shows improved tumor retention and demonstrates promising anti-tumor activity in translationally relevant preclinical models (e.g., PDAC, NSCLC) where FAP is expressed on CAFs. Methods: CFXX489A12101 (NCT06562192) is a first-in-human phase I, open-label, multi-center study of [177Lu]Lu-NNS309 in patients with pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer (BC), and colorectal cancer (CRC). The study includes a dose escalation part followed by a dose expansion part. Key eligibility criteria include prior treatment for locally advanced unresectable or metastatic disease and having all measurable lesions (per RECIST 1.1) showing [68Ga]Ga-NNS309 uptake on positron emission tomography/computed tomography (PET/CT). Patients who are eligible for treatment receive one dose of [177Lu]Lu-NNS309 on day 1 of each cycle. A 6-week and a 4-week dosing schedule will be explored. Dosimetry data will be obtained from patients in the dose escalation part after the first dose and will be used to calculate the cumulative radiation exposure. Dose escalation will be guided by a Bayesian hierarchical logistic regression model with overdose control (EWOC) principle, and assessment of all relevant data available from all dose levels including safety, tolerability, clinical dosimetry, pharmacodynamics, and preliminary efficacy. Once the recommended dose(s) (RD) and schedule(s) of [177Lu]Lu-NNS309 are determined, the expansion part may open and will include patients with locally advanced or metastatic PDAC (n∼20), locally advanced or metastatic NSCLC (n∼20), HR+/HER2- ductal BC (n∼15), HR+/HER2- lobular BC (n∼15), and triple negative BC (; n∼24).The primary objectives of the study are to evaluate the safety and tolerability of [177Lu]Lu-NNS309 and to identify the RD(s) and regimen(s) of [177Lu]Lu-NNS309 for further clinical evaluation. Secondary objectives of the study are to evaluate the preliminary anti-tumor activity of [177Lu]Lu-NNS309, characterize the pharmacokinetics of [177Lu]Lu-NNS309 in blood and urine, the radiation dosimetry for organs and tumor lesions, and to evaluate the safety and imaging properties of [68Ga]Ga-NNS309. Conclusion: The study is currently enrolling in the dose escalation part. Citation Format: Ravit Geva, Daniel Juneau, Shadi Abdar Esfahani, Cristiano Ferrario, Farshad Moradi, Amir Iravani, Jordi Ahnert, Ivan Manuel Victoria Ruiz, Thibaud Koessler, Aitana Calvo Ferrandiz, Bernard Doger de Speville, Patrick Flamen, Albiruni Razak, Desiree Deandreis, Laure Al-Mansour, Niklaus Schaefer, James Nagarajah, Hilde Nienhuis, Marco Maccauro, Angelina Filice, Jonathan Goldman, Ken Herrmann, Matthias Eiber, Alexander Drzezga, Martin Heuschkel, Jonathan McConathy, Johnson Geoffrey, Ephraim Parent, Yasutoshi Kuboki, Shizuka Origuchi, Xuan Mai Couillebault, Elisa Garcia Garayoa, Jayarama Naidu Roopa, Christopher Straub, Dominik Hainzl, Xinyu Chen, Fang Yang, Eirini Pectasides, Brandon Mancini. Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of FXX489 ([177Lu]Lu-NNS309) in patients with pancreatic, lung, breast and colorectal cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT112.
Sex differences in the clinical manifestation of autosomal dominant frontotemporal dementia
Memel, Molly , Staffaroni, Adam M. , Ilan‐Gala, Ignacio, Castro, J. García , Kornak, John , Tartaglia, Carmela M., Saloner, Rowan, Cadwallader, Claire J. , Chen, Coty , Gorno‐Tempini, Maria Luisa , Mandelli, Malu, Apostolova, Liana , Graff-Radford, N. R., Pressman, Peter , Miyagawa, Toji , Mackenzie, Ian R. , Darby, R. Ryan , Petrucelli, Len, Gendron, Tania, Heuer, Hilary W. , Forseberg, Leah K., Brushaber, Nellie, Domoto‐Reilly, Kimiko , Ghoshal, Nupur , Pascual, Belén , Lee, Suzee, Ramos, Eliana Marisa , Rademakers, Rosa , Rascovsky, Katya, Masdeu, Joseph C. , Boxer, Adam L., Rosen, Howard J. , Casaletto, Kaitlin B. , Illán‐Gala, Ignacio , Graff-Radford, Neil, Boeve, Brad F, Pascual, Belen , Domoto-Reilly, Kimiko , Garcia Castro, Jesús , Illán-Gala, Ignacio , Saloner, Rowan , VandeBunte, Anna M. , Paolillo, Emily W. , Litvan, Irene , Bayram, Ece , Goldman, Jill , Appleby, Brian S. , Gendron, Tania F. , Rojas, Julio C. , Boeve, Bradley F. , Lapid, Maria I. , Ramanan, Vijay K. , Pantelyat, Alexander , Masdeu, Joseph C , Snyder, Allison , Boxer, Adam L.

Mayo Clinic

Alzheimer's & Dementia | April 25, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.14630 | PMID 40277077 Get It

Abstract INTRODUCTION Sex differences are apparent in neurodegenerative diseases but have not been comprehensively characterized in frontotemporal dementia (FTD). METHODS Participants included 337 adults with autosomal dominant FTD enrolled in the ALLFTD Consortium. Clinical assessments and plasma were collected annually for up to 6 years. Linear mixed‐effects models investigated how sex and disease stage are associated with longitudinal trajectories of cognition, function, and neurofilament light chain (NfL). RESULTS While sex differences were not apparent at asymptomatic stages, females showed more rapid declines across all outcomes in symptomatic stages compared to males. In asymptomatic participants, the association between baseline NfL and clinical trajectories was weaker in females versus males, a difference that was not present in symptomatic participants. DISCUSSION In genetic FTD, females show cognitive resilience in early disease stages followed by steeper clinical declines later in the disease. Baseline NfL may be a less sensitive prognostic tool for clinical progression in females with FTD‐causing mutations. Highlights Females with genetic FTD exhibit overall steeper increases in plasma neurofilament light chain (NfL) than males. Females with genetic FTD outperform NfL levels in asymptomatic stages compared to males. Once symptomatic, females with genetic FTD decline more rapidly than males. Plasma NfL is a stronger prognostic marker in asymptomatic males than females.
Prognostic Significance of Germline DICER1 Pathogenic or Likely Pathogenic Variants in Outcomes of Ovarian Sertoli-Leydig Cell Tumor
Nelson, Alexander T. , Watson, David , Chen, Kenneth , Olson, Damon R. , Stall, Jennifer N., Devins, Kyle M. , Young, Robert H. , Kamihara, Junne , Mallinger, Paige, Kim, Jung , Hatton, Jessica N. , Schneider, Dominik T. , Harris, Anne K. , Dehner, Louis P. , Schultz, Kris Ann P. , Watson, Dave , Chen, Kenneth S , Mallinger, Paige H R , Messinger, Yoav H , Frazier, A Lindsay , Stewart, Douglas R , Harris, Anne K , Dehner, Louis P , Hill, Dana Ashley , Schultz, Kris Ann P , Olson, Damon R , Schneider, Dominik T , Devins, Kyle M , Messinger, Yoav H.

Mayo Clinic

JCO Precision Oncology | April 23, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/po-24-00902 | PMID 40267387 Get It

PURPOSE Sertoli-Leydig cell tumors (SLCTs) are rare sex cord-stromal tumors, representing <0.5% of all ovarian tumors. We analyze the role of germline DICER1 status in outcomes of ovarian SLCT. METHODS Patients with SLCT were enrolled in the International Pleuropulmonary Blastoma/ DICER1 Registry and/or the International Ovarian and Testicular Stromal Tumor Registry. Medical records were systematically abstracted, and those with known germline DICER1 status were selected for analysis. RESULTS Of 162 patients with SLCT, 60% had a germline DICER1 pathogenic or likely pathogenic (P/LP) variant. The adjusted 3-year recurrence-free survival (RFS) was 87.2% (95% CI, 79.4 to 95.8) for patients with a germline DICER1 P/LP variant compared with 78.1% (95% CI, 66.4 to 91.9) for those without a germline DICER1 P/LP variant ( P = .043). The adjusted 3-year and 5-year overall survival (OS) was 93.9% (95% CI, 87.3 to 100.0) for those with a germline DICER1 P/LP variant compared with the 3-year OS of 91.3% (95% CI, 83.4 to 100.0) and the 5-year OS of 78.2% (95% CI, 63.8 to 95.9) for those without a germline DICER1 P/LP variant ( P = .021). Among patients with a germline DICER1 P/LP variant, the risk of a subsequent, nonrecurrent event was 36.2% (95% CI, 21.4 to 48.1) within 10 years. Previous/concurrent and subsequent neoplasms were rare among those without a germline DICER1 P/LP variant. CONCLUSION This cohort study of patients with SLCT demonstrated that those with germline DICER1 P/LP variants had superior RFS and OS even when adjusting for other prognostic factors. Beyond prognostic implications of a germline DICER1 P/LP variant, germline testing helps identify patients at risk of subsequent neoplasms, including metachronous SLCT.
Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries
Harris, Anne K. , Nelson, Alexander T. , Watson, Dave , Mallinger, Paige, Stering, Allen I., Snyder, Stacy L., Levy, Carolyn Fein , Kamihara, Junne , Herzog, Cynthia E. , Lagmay, Joanne , Foresto, Steve, Young, Robert H. , Dehner, Louis P. , Tadavarthy, Anil K., Stall, Jennifer N., Billmire, Deborah F., Schneider, Dominik T. , Schultz, Kris Ann P. , Kamihara, Junne , Chen, Kenneth S , Devins, Kyle M , Schneider, Dominik T , Schultz, Kris Ann P , Levy, Carolyn Fein , Harris, Anne K , Messinger, Yoav H. , Frazier, A Lindsay , Chen, Kenneth , Devins, Kyle M. , Hill, Dana Ashley

Mayo Clinic

Cancer | April 23, 2025 | Volume: 131 | Issue: 9 | Pages: No page available

10.1002/cncr.35862 | PMID 40267023 Get It

AbstractBackgroundOvarian juvenile granulosa cell tumors (juvGCT) are rare sex cord‐stromal tumors that occur primarily in children and adolescents. This study summarizes the clinical presentation and outcomes of patients with juvGCT.MethodsPatients were enrolled in the International Ovarian and Testicular Stromal Tumor and/or International Pleuropulmonary Blastoma/DICER1 Registries. Available medical records were abstracted, and pathology was centrally reviewed. Surgical staging was classified using the 2014 International Federation of Gynecology and Obstetrics (FIGO) criteria.ResultsIn total, 70 patients with juvGCT enrolled and were diagnosed between 2001 and 2024; most patients (81%, 57 of 70) presented with FIGO stage I disease. Adjuvant chemotherapy was given in 30% (21 of 70); all regimens were platinum‐based. Three‐year event‐free survival among patients with stage IA tumors was 80.2% (95% confidence interval [CI], 62.4%–100.0%), IC1 was 87.4 (95% CI, 72.4%–100.0%), IC2‐IC3 was 63.6% (95% CI, 40.7%–99.5%), and II‐IV was 48% (95% CI, 24.6%–93.8%). Of the patients with recurrent juvGCT with known mitotic index (MI), all had MI greater than 19 mitoses per 10 high power fields (HPF) at diagnosis.ConclusionOutcomes were worse for patients with FIGO stage ≥IC2 disease and for tumors with >19 mitoses per 10 HPF. Given the prognostic significance of MI, the authors strongly recommend the assessment of MI for all juvGCTs. More information about tumor biology is critical to identify which patients may benefit from adjuvant chemotherapy and to facilitate the development of novel therapies.
Large Language Model Consensus Substantially Improves the Cell Type Annotation Accuracy for scRNA-seq Data
Yang, Chen

Mayo Clinic

No container title available | April 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.04.10.647852 Get It

Abstract Different large language models (LLMs) have the potential to complement one another. We introduce an iterative multi-LLM consensus framework for annotating single-cell RNA sequencing data. This framework outperforms the best state-of-the-art method by nearly 15% in mean accuracy (77.3% vs 61.3%) across 50 diverse datasets from 26 tissues, encompassing over 8 million cells. By leveraging cross-model deliberation, our framework quantifies uncertainty, identifies ambiguous clusters for expert review, provides transparent reasoning chains, and minimizes the effort and expertise needed for cell type annotation in large-scale studies. Additionally, our framework enables users to seamlessly integrate new LLMs.
Dynamic Fluid‐Assisted Continuous Multimaterial 3D Printing for Seamless Gradient Structures
Wang, Wenbo , Liu, Siying , Liu, Luyang , Nogueira, Cauê , Chen, Xiangfan , Chen, Xiangfan , Ma, Xiaoli , Xu, Xin , Shefi, Orit , Lancaster, Jessica

Mayo Clinic

Advanced Materials Technologies | April 23, 2025 | Volume: 10 | Issue: 15 | Pages: No page available

10.1002/admt.202500621 Get It

AbstractFunctionally gradient materials emulate nature's ability to seamlessly blend properties through variations in material composition, unlocking advanced engineering applications such as biomedical devices and high‐performance composites. Additive manufacturing, particularly stereolithography, enables sophisticated 3D geometries with diverse materials. However, current stereolithography‐based multi‐material 3D printing is constrained by time‐intensive material switching and compromised interfacial properties. To overcome these challenges, we present dynamic fluid‐assisted micro continuous liquid interface production (DF‐µCLIP), a high‐speed multi‐material 3D printing platform that integrates varying compositions in a fully continuous fashion. By utilizing the polymerization‐free “dead zone”, vliquid resins are seamlessly replenished within a resin bath equipped with dynamic fluidic channels and a synchronized material supply system. DF‐µCLIP achieves ultra‐fast printing speeds of 90 mm/hour with 7.4 µ m pixel‐1 resolution while enabling on‐the‐fly material transitions. This strategy enhances mechanical strength at multi‐material interface through entangled polymer networks and promotes seamless material transitions between distinct materials ilike fragile hydrogels and rigid polymers, addressing interfacial failure caused by mismatch of swelling behavior. Additionally, dynamic material replenishment with real‐time composition control enables continuous gradient printing instead of the conventional step‐wise controlled gradient. Demonstrations include polymers with gradient color transitions and gradient carbon nanotube (CNT) composites with seamlessly varying conductivity.
Radiological Assessment of Lumbar Fusion Status: Which Imaging Modality is Best Assessing Non-union in Lumbar Spine Pseudarthrosis?
González-Gallardo, Enrique , Iyer, Harshvardhan , Llano, Juan P Navarro-Garcia de , Sánchez-Garavito, Jesús E. , Loizos, Michaelides, Ríos-Zermeño, Jorge , Buchanan, Ian A. , Nottmeier, Eric W. , Chen, Selby G. , Pirris, Stephen M. , Quiñones‐Hinojosa, Alfredo , Navarro-Ramírez, Rodrigo , Ekert, Justyna O. , Iyer, Harshvardhan G, Navarro-García de Llano, Juan Pablo, Sánchez-Garavito, Jesús E , Rios Zermeno, Jorge , Navarro-Ramírez, Rodrigo , Iyer, Harshvardhan G , Abode-Iyamah, Kingsley , Chen, Selby , Akinduro, Oluwaseun O.

Mayo Clinic

Global Spine Journal | April 22, 2025 | Volume: 15 | Issue: 7 | Pages: 3465-3478

10.1177/21925682251336715 | PMID 40262542 Get It

Study Design Systematic Review. Objective To assess the current literature regarding the accuracy of different imaging modalities and criteria used to assess lumbar fusion, and their correlation with surgical direct observation as the current Gold Standard. Methods Following PRISMA guidelines, we conducted a comprehensive search of PubMed, Embase, Google Scholar, and Cochrane Library, studies were included if they focused on patients with a prior history of lumbar interbody fusion and at least 1 year of radiographic follow-up. The review assessed the sensitivity, specificity, and accuracy of different imaging techniques, and their correlation with surgical findings. Results Thirteen studies (1989-2019) were reviewed, including 715 patients, common imaging modalities included plain radiographs (53.8%), Computed Tomography (CT) (69.2%), and dynamic radiographs (30.7%). CT appeared as the most utilized modality post-2006. There was substantial variability in diagnostic accuracy, with CT showing high variability in sensitivity and specificity. Descriptive criteria for fusion were widely used, but interobserver agreement was generally low. Conclusion The review highlights a lack of standardized criteria for assessing lumbar fusion. Despite advancements in imaging techniques, the variability in diagnostic parameters suggests a need for consensus and multicentric studies to stablish reliable, universal criteria for evaluating fusion success.
Bioartificial liver support for acute liver failure
Nelson, Erek , Chen, Harvey , Amiot, Bruce , Nyberg, Scott L. , Nelson, Erek David , Nyberg, Scott L , Joo, Dong Jin

Mayo Clinic

Annals of Liver Transplantation | April 22, 2025 | Volume: 5 | Issue: 1 | Pages: 31-39

10.52604/alt.25.0004 Get It